Ipsen Aktie [WKN: A0ESMG / ISIN: FR0010259150]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Ipsen

24.08.15		IPSEN : Disclosure of Transactions in Own Shares between 17/08/2015 and 21/08/2015 (Businesswire)
14.08.15		IPSEN: Disclosure of Transactions in Own Shares Between 10/08/2015 and 14/08/2015 (Businesswire)
10.08.15		IPSEN: Disclosure of Transactions in Own Shares Between 03/08/2015 and 07/08/2015 (Businesswire)
07.08.15		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
31.07.15		Ipsen: 2015 Half-Year Results (Businesswire)
16.07.15		Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for injection in the treatment of upper limb spasticity in adults in the United States (Businesswire)
07.07.15		IPSEN S.A.: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
03.07.15		Half-year IPSEN liquidity contract statement entered into with NATIXIS (Businesswire)
02.07.15		Ipsen Provides an Update on 2020 Strategy and Outlook at Investor Day (Businesswire)
01.07.15		IPSEN: Disclosure of Transactions in Own Shares Between 24/06/2015 and 30/06/2015 (Businesswire)
24.06.15		Ipsen : Disclosure of Transactions in Own Shares between 17/06/2015 and 23/06/2015 (Businesswire)
17.06.15		IPSEN : Disclosure of Transactions in Own Shares Between 10/06/2015 and 16/06/2015 (Businesswire)
10.06.15		Ipsen : Disclosure of Transactions in Own Shares Between 03/06/2015 and 09/06/2015 (Businesswire)
03.06.15		Ipsen initiates a share buyback program (Businesswire)
03.06.15		Ipsen initiates a share buyback program (Businesswire)
02.06.15		Ipsen confirms its eligibility for PEA-PME (Businesswire)
02.06.15		Ipsen confirms its eligibility for PEA-PME (Businesswire)
29.05.15		Combined Shareholders’ Meeting of IPSEN S.A. held on 27 May 2015 (Businesswire)
07.05.15		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
06.05.15		Ipsen : Combined Shareholders’ Meeting of 27 May 2015 (Businesswire)
05.05.15		Ipsen: Description of the Regulatory Framework of the Share Repurchase Program Proposed by the Board of Directors to the Approval of the Combined Shareholders’ Meeting to Be Held on 27 May 2015 (Businesswire)
29.04.15		Ipsen reports strong sales growth in Q1 2015 and raises guidance for the year (Businesswire)
16.04.15		Active Biotech and Ipsen Announce Their Decision to Discontinue the Development of tasquinimod in Prostate Cancer (Businesswire)
08.04.15		Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
08.04.15		Ipsen and Hannover Medical School Start Joint Research in Recombinant Botulinum Neurotoxins for Targeted Secretion Inhibitors (Businesswire)
01.04.15		Ipsen Expands Ties to Harvard University with Signing of a New Research Alliance Agreement (Businesswire)
01.04.15		Ipsen inaugurates new Cambridge, MA R&D center, at the heart of the most important biomedical research & innovation hub in the USA, to expand U.S. presence (Businesswire)
31.03.15		The Ipsen Group Publishes Its 2014 Registration Document (Businesswire)
09.03.15		Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
03.03.15		Ipsen’s 2014 Results and 2015 Financial Objectives (Businesswire)
02.03.15		Ipsen Announces Third Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2015 (Businesswire)
02.03.15		Dominique Laymand is Appointed as Ipsen’s Senior Vice President, Chief Ethics and Compliance Officer (Businesswire)
24.02.15		Ipsen Enters into Option Agreement to Acquire Canbex Therapeutics (Businesswire)
06.02.15		Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
03.02.15		Ipsen: Sales in the Fourth Quarter and Full Year 2014 (Businesswire)
03.02.15		Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults (Businesswire)
26.01.15		Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults (Businesswire)
08.01.15		Half-Year IPSEN Liquidity Contract Statement Entered into with NATIXIS (Businesswire)
07.01.15		Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
16.12.14		Ipsen’s Somatuline® Depot® is the First Therapy Approved by the FDA in the United States for the Treatment of Patients with Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumors (Businesswire)
16.12.14		François Garnier Appointed Executive Vice President, General Counsel of Ipsen (Businesswire)
12.12.14		Ipsen Announces That the International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating the Use of Ovarian Suppression to Adjuvant Treatment with Tamoxifen (Businesswire)
09.12.14		Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
28.11.14		Ipsen Announces FDA Acceptance of Filing for Dysport® in the Treatment of Upper Limb Spasticity in Adult Patients (Businesswire)
20.11.14		Ipsen and CNRS Create the "Archi-Pex" Joint Research and Innovation Lab, in Collaboration with the University of Rennes 1 and CEA (Businesswire)
12.11.14		Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
06.11.14		Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus (Businesswire)
29.10.14		Ipsen: sales in the 3rd quarter and first nine months of 2014 (Businesswire)
22.10.14		Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate (Businesswire)
10.10.14		Ipsen Announces Positive Results from Phase III Clinical Study of Decapeptyl® (triptorelin pamoate) 11.25 mg Administered by Subcutaneous Route to Prostate Cancer Patients (Businesswire)

Erste Seite Zurück | ... | 5 | 6 | 7 | 8 | Weiter

Newssuche

Meistgelesene Nachrichten

Diese AI-Aktie ist Cathie Woods neuer Favorit

JPMorgan: Bitcoin-Miner setzen auf Unternehmensmodell von MicroStrategy

NEL sichert sich Steuergutschrift in Millionenhöhe - Aktie sackt ab

ATX-Papier voestalpine-Aktie: So viel Verlust hätte ein voestalpine-Investment von vor einem Jahr eingefahren

Aktien von PVA TePla und SMA Solar springen hoch, VERBIO-Aktie stürzt ab: Jefferies-Analyst passt zahlreiche Bewertungen an

D-Wave Quantum-Aktie, IonQ-Aktie und Rigetti-Aktie fallen: Aktienrutsch geht trotz Beruhigungssignalen weiter

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	15.01.2025 18:56
Kaufwert:	EUR
	Hinzufügen Speichern